INT78845

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 1998
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 16
Total Number 24
Disease Relevance 11.67
Pain Relevance 3.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pparg) signal transduction (Pparg) nucleus (Pparg)
enzyme binding (Pparg) DNA binding (Pparg) cytoplasm (Pparg)
Anatomy Link Frequency
liver 2
pancreas 2
neuronal 1
adipocytes 1
Pparg (Rattus norvegicus)
Pparg - P12A (2)
Pain Link Frequency Relevance Heat
cINOD 14 99.64 Very High Very High Very High
Inflammation 17 98.68 Very High Very High Very High
cytokine 5 98.40 Very High Very High Very High
agonist 13 97.56 Very High Very High Very High
Inflammatory response 10 93.28 High High
Chronic pancreatitis 8 90.64 High High
IPN 1 89.92 High High
fibrosis 4 88.88 High High
qutenza 1 85.48 High High
tolerance 27 85.32 High High
Disease Link Frequency Relevance Heat
Cardiovascular Disease 117 100.00 Very High Very High Very High
Atherosclerosis 18 100.00 Very High Very High Very High
Disease 32 99.52 Very High Very High Very High
INFLAMMATION 30 99.40 Very High Very High Very High
Coronary Artery Disease 117 99.36 Very High Very High Very High
Hyperinsulinism 27 99.24 Very High Very High Very High
Hypertrophy 36 98.96 Very High Very High Very High
Myocardial Infarction 144 98.52 Very High Very High Very High
Obesity 110 97.52 Very High Very High Very High
Diabetes Mellitus 279 97.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Because sustained medication with NSAIDs reduces the risk and delays the onset of AD, these results further suggest that NSAIDs provide therapeutic value by binding to PPARgamma present in AD brain, thereby preventing iNOS expression and neuronal cell death.
PPARgamma Binding (binding) of in neuronal associated with cinod, disease and death
1) Confidence 0.44 Published 2000 Journal J. Neurosci. Section Abstract Doc Link 10995830 Disease Relevance 0.87 Pain Relevance 0.49
This evidence together with the chemical analogy with ibuprofen led us to investigate whether flurbiprofen and HCT1026 interact with PPAR-gamma and interfere with microglial activation.
PPAR-gamma Binding (interact) of
2) Confidence 0.37 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15686492 Disease Relevance 0.30 Pain Relevance 0.50
Ligands of the peroxisome proliferator-activated receptor gamma (PPARgamma), such as thiazolidinediones, are potent inhibitors of stellate cell activation and fibrogenesis in pancreas and liver.
peroxisome proliferator-activated receptor gamma Binding (Ligands) of in liver associated with fibrosis
3) Confidence 0.37 Published 2005 Journal J. Cell. Mol. Med. Section Abstract Doc Link 16202214 Disease Relevance 0.48 Pain Relevance 0.14
Ligands of the peroxisome proliferator-activated receptor gamma (PPARgamma), such as thiazolidinediones, are potent inhibitors of stellate cell activation and fibrogenesis in pancreas and liver.
PPARgamma Binding (Ligands) of in liver associated with fibrosis
4) Confidence 0.37 Published 2005 Journal J. Cell. Mol. Med. Section Abstract Doc Link 16202214 Disease Relevance 0.48 Pain Relevance 0.14
Interdomain communication regulating ligand binding by PPAR-gamma.
PPAR-gamma Binding (binding) of
5) Confidence 0.35 Published 1998 Journal Nature Section Title Doc Link 9845075 Disease Relevance 0.25 Pain Relevance 0.12
Here we show that ligand binding by PPAR-gamma is regulated by intramolecular communication between its amino-terminal A/B domain and its carboxy-terminal LBD.
PPAR-gamma Binding (binding) of
6) Confidence 0.35 Published 1998 Journal Nature Section Abstract Doc Link 9845075 Disease Relevance 0.25 Pain Relevance 0.13
Ligand binding by PPAR-gamma, as well as by the entire nuclear-receptor superfamily, is an independent property of the carboxy-terminal ligand-binding domain (LBD) of the receptor.
PPAR-gamma Binding (binding) of
7) Confidence 0.35 Published 1998 Journal Nature Section Abstract Doc Link 9845075 Disease Relevance 0.28 Pain Relevance 0.14
The ability of the A/B domain to regulate ligand binding has important implications for the evaluation and mechanism of action of potentially therapeutic ligands that bind PPAR-gamma and that are likely to extend to other members of the nuclear-receptor superfamily.
PPAR-gamma Binding (bind) of
8) Confidence 0.35 Published 1998 Journal Nature Section Abstract Doc Link 9845075 Disease Relevance 0.19 Pain Relevance 0.10
Cannabidiol was also found to bind to PPARgamma and stimulate the differentiation of 3T3-L1 fibroblasts into adipocytes, a PPARgamma-mediated response.
PPARgamma Binding (bind) of in adipocytes associated with obesity
9) Confidence 0.34 Published 2009 Journal Eur. J. Pharmacol. Section Abstract Doc Link 19285060 Disease Relevance 0.18 Pain Relevance 0.20
PPARG haplotype was associated
PPARG Binding (associated) of
10) Confidence 0.29 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.39 Pain Relevance 0
association of the PPARG Ala12 allele carriers with nonfatal MI or
PPARG Binding (association) of associated with myocardial infarction
11) Confidence 0.29 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.98 Pain Relevance 0
The association of the PPARG Pro12Ala polymorphism with metabolic traits and the risk/development of DM has
PPARG (P12A) Binding (association) of associated with diabetes mellitus
12) Confidence 0.29 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.77 Pain Relevance 0
to the PPARG Pro12 variant, the PPARG Ala12 variant has lower
PPARG Binding (lower) of
13) Confidence 0.29 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.85 Pain Relevance 0.03
PPARG haplotype pharmacogenetic associations
PPARG Binding (associations) of
14) Confidence 0.28 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.48 Pain Relevance 0
only available in 12 of the 57 studies), the association of the PPARG Ala12 allele with increased insulin sensitivity was more evident in all groups [80].
PPARG Binding (association) of associated with hyperinsulinism
15) Confidence 0.28 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.85 Pain Relevance 0
PPARD, and PPARG with cardiovascular disease (coronary and carotid atherosclerosis, left
PPARG Binding (left) of associated with atherosclerosis and cardiovascular disease
16) Confidence 0.25 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 1.04 Pain Relevance 0
PPARG 54,347 C > T genetic associations
PPARG Binding (associations) of
17) Confidence 0.24 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.56 Pain Relevance 0.04
PPARG Pro12Ala pharmacogenetic associations
PPARG (P12A) Binding (associations) of
18) Confidence 0.24 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.57 Pain Relevance 0.07
PURPOSE: Thiazolidinedione derivatives (TZDs) are known to be ligands of peroxisome proliferator-activated receptor gamma (PPARgamma).
PPARgamma Binding (ligands) of
19) Confidence 0.14 Published 2005 Journal Rocz. Akad. Med. Bialymst. Section Abstract Doc Link 16358954 Disease Relevance 0.07 Pain Relevance 0.25
PURPOSE: Thiazolidinedione derivatives (TZDs) are known to be ligands of peroxisome proliferator-activated receptor gamma (PPARgamma).
peroxisome proliferator-activated receptor gamma Binding (ligands) of
20) Confidence 0.14 Published 2005 Journal Rocz. Akad. Med. Bialymst. Section Abstract Doc Link 16358954 Disease Relevance 0.07 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox